The phase III ARANOTE trial, investigating Nubeqa (darolutamide) plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, has met its primary endpoint of radiological progression-free survival. Nubeqa plus ADT demonstrated a statistically significant and clinically meaningful increase in rPFS compared to placebo plus ADT.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe